YIDU TECH (02158) surged over 5% in late trading. As of press time, the stock was up 5.24% to HK$6.43 with a turnover of HK$36.59 million.

On the news front, the "T20+ Conference" was recently held in Suzhou, guided by the China Association for Quality and Safety Promotion of Food and Drug Enterprises and hosted by Tongxieyi. The conference focused on innovation across the entire new drug R&D chain, addressing key challenges in industry upgrading. Leading domestic AI healthcare company YIDU TECH showcased its intelligent clinical research integrated solutions at the conference, systematically presenting replicable pathways for AI-driven clinical research efficiency improvements.

Currently, YIDU TECH has served over 350 domestic and international pharmaceutical companies, accumulating experience from 686 clinical trial projects and conducting 275 prospective and retrospective real-world research projects.

At the conference, Liu Ying, Vice President of YIDU TECH's Life Sciences Clinical Trial Business, stated that over the years, YIDU TECH has leveraged its accumulated medical big data processing capabilities, disease understanding capabilities, and disease knowledge graph construction advantages. Relying on its independently developed "AI Medical Brain" YiduCore, the company has built an intelligent clinical research integrated solution covering the entire clinical trial process. This solution significantly accelerates key drug development stages including clinical trial protocol optimization, intelligent patient recruitment, and clinical operations by over 30%, effectively promoting R&D efficiency improvements, product launch pathway optimization, and innovation cost reduction.